Vincristine-associated neurological morbidity in the treatment of hepatoblastoma

Journal of Pediatric Hematology/oncology
Anne J LombardiJames I Geller

Abstract

Chemotherapy is an essential component of therapy for infants and children with hepatoblastoma. Vincristine has been a mainstay of chemotherapeutic regimens used by North American cooperative groups, based on indirect evidence of benefit and an assumption of minimal added toxicity. European cooperative group trials have reported comparable survival rates using regimens that omit vincristine. Further examination of the risk and benefit profile of vincristine relevant to hepatoblastoma clinical care paradigms is thus warranted. We evaluated the incidence of vincristine-related sensorimotor peripheral, autonomic, and cranial nerve neurological morbidities in 45 consecutive hepatoblastoma patients treated at our institution. Data suggest an increased risk of vincristine-associated neuropathic grade 2 and 3 events (neuropathic pain and gross motor impairment) in children ages 24 months old or younger, and particularly in children born prematurely. Formal prospective investigation of the relative risks and benefits of vincristine in hepatoblastoma treatment is warranted to assess the value of continued use of vincristine in this patient population.

References

Jun 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N V Cheung, G Heller
Dec 1, 1989·Cancer Treatment Reviews·R J Cersosimo
Jan 1, 1985·Medical and Pediatric Oncology·E C DouglassC B Pratt
Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D von SchweinitzH Mildenberger
Nov 26, 1999·Medical and Pediatric Oncology·H Reinders-MesselinkW Kamps
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J PritchardJ Plaschkes
Sep 25, 2001·Medical and Pediatric Oncology·H A Reinders-MesselinkW A Kamps
Jul 13, 2002·Cancer·Jörg FuchsUNKNOWN Study Committee of the Cooperative Pediatric Liver Tumor Study Hb 94 for the German Society for Pediatric Oncology and Hemat
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard M KatzensteinLaura C Bowman
Jan 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G PerilongoUNKNOWN International Society of Paediatric Oncology-SIOPEL 2
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marcio H MalogolowkinRobert P Castleberry
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marcio H MalogolowkinJorge A Ortega
Oct 23, 2009·The New England Journal of Medicine·Giorgio PerilongoPiotr Czauderna
Jul 28, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·József ZsírosGiorgio Perilongo
Jul 9, 2013·The Lancet Oncology·József ZsirosUNKNOWN International Childhood Liver Tumours Strategy Group (SIOPEL)

❮ Previous
Next ❯

Citations

Nov 30, 2016·Pediatric Blood & Cancer·Melissa A AcquazzinoAmanda M Brandow
Nov 5, 2019·Pediatric Hematology and Oncology·Nassr NamaShahrad Rod Rassekh
Jul 6, 2021·Cancer Treatment and Research Communications·Ellen M Lavoie SmithUNKNOWN Toxic Neuropathy Consortium of the Peripheral Nerve Society

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.